Karas Eric's Form 4 filing
ARS Pharmaceuticals, Inc. (SPRY) · filed Dec 4, 2024
- Accession no.
- 0001415889-24-028349
- Filed
- Dec 4, 2024
- Trade date
- Dec 2-4, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 4 non-derivative transactions and 2 derivative transactions. Open-market sales total $140.4K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Karas EricCIK 0001951287 | Officer (Chief Commercial Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 2, 2024 | Common Stock | MOption exerciseAcquired | +3,717 | $1.50 | +$5,575.5 | 9,410 | Direct | |
| Dec 2, 2024 | Common Stock | SSaleDisposed | −3,717 | $14.11 | −$52,446.87 | 5,693 | Direct | |
| Dec 4, 2024 | Common Stock | MOption exerciseAcquired | +6,283 | $1.50 | +$9,424.5 | 11,976 | Direct | |
| Dec 4, 2024 | Common Stock | SSaleDisposed | −6,283 | $14.00 | −$87,962 | 5,693 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 2, 2024 | Common Stock | MOption exerciseDisposed | −3,717 | $0.00 | $0 | 590,871 | Direct | |
| Dec 4, 2024 | Common Stock | MOption exerciseDisposed | −6,283 | $0.00 | $0 | 584,588 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.